Thomas Kalapura, MD
Cardiovascular Disease · Tulsa, OKNPI 1740258995
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,379 of the $17,234 with a category attached, or 66.0%. 13 manufacturers reported payments, led by Medtronic at 54.2% of the total. Reporting peaked in 2024 at $11,188 and has fallen 86.6% since, to $1,494 in 2025. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $200.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$2K
- Silk Road Medical, Inc.$1K
- Abiomed$1K
- Philips North America LLC$1K
- Edwards Lifesciences$865
- plus $2K from 7 others
Across 2 payments — averaging $9475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$19K
What the payments were for
- Travel & lodging$11,37966%
- Food & beverage$5,85534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $9,348 |
| Abbott | 18 | $1,612 |
| Silk Road Medical, Inc. | 8 | $1,433 |
| Abiomed | 8 | $1,018 |
| Philips North America LLC | 8 | $1,006 |
| Edwards Lifesciences | 10 | $865 |
| Boston Scientific | 8 | $771 |
| Inari Medical, Inc. | 2 | $403 |
| Penumbra, Inc. | 2 | $282 |
| AstraZeneca | 2 | $168 |
| Veryan Medical Incorporated | 1 | $121 |
| Asahi Intecc USA, Inc. | 1 | $118 |
| Alnylam Pharmaceuticals Inc. | 1 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$1,383
- ENROUTE Transcarotid Stent System$1,028
- ENHANCE Transcarotid Peripheral Access Kit$1,028
- ENROUTE 0.014 Guidewire$1,028
- (9525) Intracardiac Und$931
- Impella$927
- TRICLIP$774
- FLOWTRIEVER CATHETER, S$626
- ENROUTE Transcarotid Stent$354
- Indigo System$282
- INSPIRIS RESILIA aortic valve$192
- CT THROMBECTOMY SYSTEM KIT$179
- ESPRIT$179
- COREVALVE EVOLUT R$147
- MAMBA$143
- EKOSONIC$125
- MitraClip$121
- BioMimics 3D Vascular Stent System$121
- ASAHI Peripheral Guide Wires$118
- OPTIS$116
How this compares
$17,234 in reported general payments places this provider in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 225 | $174,240 |
| Repatha SureclickEvolocumab | 103 | $114,659 |
| JardianceEmpagliflozin | 107 | $70,540 |
| FarxigaDapagliflozin Propanediol | 77 | $56,081 |
| Praluent PenAlirocumab | 53 | $52,245 |
| EntrestoSacubitril/Valsartan | 62 | $47,697 |
| XareltoRivaroxaban | 41 | $38,227 |
| BrilintaTicagrelor | 30 | $19,527 |
| Atorvastatin Calcium | 456 | $10,592 |
| Rosuvastatin Calcium | 161 | $7,382 |
| VascepaIcosapent Ethyl | 17 | $6,357 |
| Ranolazine ErRanolazine | 54 | $4,748 |
| Metoprolol Succinate | 233 | $3,877 |
| ClopidogrelClopidogrel Bisulfate | 159 | $2,814 |
| Losartan Potassium | 186 | $2,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $168 | $75,608107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
- Neil AgrawalTulsa$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.